FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Parsons

Research Profile

Disorders

Anatomy

Chemicals & Drugs

Physiology

Co-author Network

Publications

TOP 3
Victoria L Challinor; William Kitching; Lynette K Lambert; Reginald P Lehmann; Peter G Parsons; Julia M U Stuthe; James J De Voss
Structure and bioactivity of steroidal saponins isolated from the roots of Chamaelirium luteum (false unicorn).
Jingjing Quan; Guangbiao Zhou; Glen M Boyle; Newell W Johnson; Peter G Parsons; Jin Gao
Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms.
Victoria L Challinor; Sonet Chap; Reginald P Lehmann; Peter G Parsons; Eve F White; Joanne T Blanchfield; James J De Voss
Steroidal saponins from the roots of Smilax sp.: structure and bioactivity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Parsons (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Victoria L Challinor; William Kitching; Lynette K Lambert; Reginald P Lehmann; Peter G Parsons; Julia M U Stuthe; James J De Voss
Structure and bioactivity of steroidal saponins isolated from the roots of Chamaelirium luteum (false unicorn).
Journal of natural products 2012;75(8):1469-79.
2012: Jingjing Quan; Guangbiao Zhou; Glen M Boyle; Newell W Johnson; Peter G Parsons; Jin Gao
Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms.
Cancer metastasis reviews 2012;31(1-2):209-19.
2012: Victoria L Challinor; Sonet Chap; Reginald P Lehmann; Peter G Parsons; Eve F White; Joanne T Blanchfield; James J De Voss
Steroidal saponins from the roots of Smilax sp.: structure and bioactivity.
Steroids 2012;77(5):504-11.
2011: Lidia A Maslovskaya; Andrei I Savchenko; Victoria A Gordon; Paul W Reddell; Carly J Pierce; Peter G Parsons; Craig M Williams
Isolation and confirmation of the proposed cleistanthol biogentic link from Croton insularis.
Organic letters 2011;13(5):1032-5.
2011: Jolieke C van der Pols; Chunxia Xu; Glen M Boyle; Maria Celia Hughes; Samuel J Carr; Peter G Parsons; Adèle C Green
Serum omega-3 and omega-6 fatty acids and cutaneous p53 expression in an Australian population.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011;20(3):530-6.
2010: Sharon A Mason; Sarah-Jane Cozzi; Carly J Pierce; Sandra Pavey; Peter G Parsons; Glen M Boyle
The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells.
Investigational new drugs 2010;28(5):575-86.
2010: Rebecca L Grange; Michael J Gallen; Heiko Schill; Jenny P Johns; Lin Dong; Peter G Parsons; Paul W Reddell; Victoria A Gordon; Paul V Bernhardt; Craig M Williams
[4+2] cycloaddition reactions between 1,8-disubstituted cyclooctatetraenes and diazo dienophiles: stereoelectronic effects, anticancer properties and application to the synthesis of 7,8-substituted bicyclo[4.2.0]octa-2,4-dienes.
Chemistry (Weinheim an der Bergstrasse, Germany) 2010;16(29):8894-903.
2010: Peter C Healy; Bradley T Loughrey; Michael L Williams; Peter G Parsons
Synthesis, structure and cytotoxicity studies of four-coordinate bis (cis-bis(diphenylphosphino)ethene) gold(I) complexes, [Au(dppey)(2)]X.
Journal of inorganic biochemistry 2010;104(6):625-31.
2010: Mitchell S Stark; Sonika Tyagi; Derek J Nancarrow; Glen M Boyle; Anthony L Cook; David C Whiteman; Peter G Parsons; Christopher Schmidt; Richard A Sturm; Nicholas K Hayward
Characterization of the Melanoma miRNAome by Deep Sequencing.
PloS one 2010;5(3):e9685.
2009: Lin Dong; Heiko Schill; Rebecca L Grange; Achim Porzelle; Jenny P Johns; Peter G Parsons; Victoria A Gordon; Paul W Reddell; Craig M Williams
Anticancer agents from the Australian tropical rainforest: Spiroacetals EBC-23, 24, 25, 72, 73, 75 and 76.
Chemistry (Weinheim an der Bergstrasse, Germany) 2009;15(42):11307-18.
2009: Bradley T Loughrey; Michael L Williams; Peter C Healy; Alessio Innocenti; Daniela Vullo; Claudiu T Supuran; Peter G Parsons; Sally-Ann Poulsen
Novel organometallic cationic ruthenium(II) pentamethylcyclopentadienyl benzenesulfonamide complexes targeted to inhibit carbonic anhydrase.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 2009;14(6):935-45.
2009: Silke Kuphal; Adam C Martyn; Julie Pedley; Lisa M Crowther; Vanessa F Bonazzi; Peter G Parsons; Anja Bosserhoff; Nicholas K Hayward; Glen M Boyle
H-cadherin expression reduces invasion of malignant melanoma.
Pigment cell & melanoma research 2009;22(3):296-306.
2009: Aaron G Smith; Kimberley A Beaumont; Darren J Smit; Amy E Thurber; Anthony L Cook; Glen M Boyle; Peter G Parsons; Richard A Sturm; George E O Muscat
PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
The international journal of biochemistry & cell biology 2009;41(4):844-52.
2009: Glen M Boyle; Julie Pedley; Adam C Martyn; Kelly J Banducci; Geoffrey M Strutton; David A Brown; Samuel N Breit; Peter G Parsons
Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity.
The Journal of investigative dermatology 2009;129(2):383-91.
2009: Melissa A Merritt; Peter G Parsons; Tanya R Newton; Adam C Martyn; Penelope M Webb; Adèle C Green; David J Papadimos; Glen M Boyle
Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer.
BMC cancer 2009;9():378.
2008: Bradley T Loughrey; Peter C Healy; Peter G Parsons; Michael L Williams
Selective cytotoxic Ru(II) arene Cp* complex salts [R-PhRuCp*](+)X(-) for X = BF4(-), PF6(-), and BPh4(-).
Inorganic chemistry 2008;47(19):8589-91.
2007: Becky L Conway-Campbell; Jong Wei Wooh; Andrew J Brooks; David Gordon; Richard J Brown; Agnieszka M Lichanska; Hong Soon Chin; Chenoa L Barton; Glen M Boyle; Peter G Parsons; David A Jans; Michael J Waters
Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(33):13331-6.
2007: Young-Keun Mo; Orhan Kankavi; Paul P Masci; George D Mellick; Michael W Whitehouse; Glen M Boyle; Peter G Parsons; Michael S Roberts; Sheree E Cross
Surfactant protein expression in human skin: evidence and implications.
The Journal of investigative dermatology 2007;127(2):381-6.
2006: Pia Kahnberg; Andrew J Lucke; Matthew P Glenn; Glen M Boyle; Joel D A Tyndall; Peter G Parsons; David P Fairlie
Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid.
Journal of medicinal chemistry 2006;49(26):7611-22.
2006: Jodie M Challacombe; Andreas Suhrbier; Peter G Parsons; Brad Jones; Peter Hampson; Dean Kavanagh; G Ed Rainger; Melanie Morris; Janet M Lord; Thuy T T Le; Diem Hoang-Le; Steven M Ogbourne
Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(11):8123-32.
2006: Sarah-Jane Cozzi; Peter G Parsons; Steven M Ogbourne; Julie Pedley; Glen M Boyle
Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway.
Cancer research 2006;66(20):10083-91.
2006: Tanya R Newton; Peter G Parsons; Douglas J Lincoln; Margaret C Cummings; david wyld; Penelope M Webb; Adele C Green; Glen M Boyle
Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer.
International journal of cancer. Journal international du cancer 2006;119(4):875-83.
2006: David Chin; Glen M Boyle; Sandro Porceddu; David R Theile; Peter G Parsons; William B Coman
Head and neck cancer: past, present and future.
Expert review of anticancer therapy 2006;6(7):1111-8.
2006: Jolieke C van der Pols; Chunxia Xu; Glen M Boyle; Peter G Parsons; David C Whiteman; Adèle C Green
Expression of p53 tumor suppressor protein in sun-exposed skin and associations with sunscreen use and time spent outdoors: a community-based study.
American journal of epidemiology 2006;163(11):982-8.
2006: Andrew J Lucke; Glen M Boyle; Peter G Parsons; David P Fairlie
New cysteine derivatives with antiproliferative activity on melanoma cells.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2006;2(2):123-32.
2006: David Chin; Glen M Boyle; David R Theile; Peter G Parsons; William B Coman
The human genome and gene expression profiling.
Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2006;59(9):902-11.
2006: Nirmitha I Herath; Mark Spanevello; Sabe Sabesan; Tanya Newton; Margaret Cummings; Shannon Duffy; Douglas Lincoln; Glen Boyle; Peter G Parsons; Andrew W Boyd
Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival.
BMC cancer 2006;6():144.
2006: Sitarina Widyarini; Munif Allanson; Nerida L Gallagher; Julie Pedley; Glen M Boyle; Peter G Parsons; David C Whiteman; Catherine Walker; Vivienne E Reeve
Isoflavonoid photoprotection in mouse and human skin is dependent on metallothionein.
The Journal of investigative dermatology 2006;126(1):198-204.
2005: Richard A Newton; Sonia E Smit; Christopher C Barnes; Julie Pedley; Peter G Parsons; Richard A Sturm
Activation of the cAMP pathway by variant human MC1R alleles expressed in HEK and in melanoma cells.
Peptides 2005;26(10):1818-24.
2005: David Chin; Glen M Boyle; Rebecca M Williams; Kaltin Ferguson; Nirmala Pandeya; Julie Pedley; Catherine M Campbell; David R Theile; Peter G Parsons; William B Coman
Alpha B-crystallin, a new independent marker for poor prognosis in head and neck cancer.
The Laryngoscope 2005;115(7):1239-42.
2005: Glen M Boyle; Adam C Martyn; Peter G Parsons
Histone deacetylase inhibitors and malignant melanoma.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 2005;18(3):160-6.
2005: David Chin; Glen M Boyle; Rebecca M Williams; Kaltin Ferguson; Nirmala Pandeya; Julie Pedley; Catherine M Campbell; David R Theile; Peter G Parsons; William B Coman
Novel markers for poor prognosis in head and neck cancer.
International journal of cancer. Journal international du cancer 2005;113(5):789-97.
2004: David Chin; Glen M Boyle; David R Theile; Peter G Parsons; William B Coman
Molecular introduction to head and neck cancer (HNSCC) carcinogenesis.
British journal of plastic surgery 2004;57(7):595-602.
2004: Matthew P Glenn; Pia Kahnberg; Glen M Boyle; Karl A Hansford; Dhiraj Hans; Adam C Martyn; Peter G Parsons; David P Fairlie
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
Journal of medicinal chemistry 2004;47(12):2984-94.
2004: Sandra Pavey; Peter Johansson; Leisl Packer; Jennifer Taylor; Mitchell Stark; Pam Pollock; Graeme J Walker; Glen M Boyle; Ursula Harper; Sarah-Jane Cozzi; Katherine Hansen; Laura Yudt; Chris Schmidt; Peter Hersey; Kay A O Ellem; Michael G E O'Rourke; Peter G Parsons; Paul Meltzer; Markus Ringnér; Nicholas K Hayward
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Oncogene 2004;23(23):4060-7.
2004: Steven M Ogbourne; Andreas Suhrbier; Brad Jones; Sarah-Jane Cozzi; Glen M Boyle; Melanie Morris; Devi McAlpine; Jenny Johns; Tania M Scott; Kirsty P Sutherland; Joy M Gardner; Thuy T T Le; Aleksandra Lenarczyk; James H Aylward; Peter G Parsons
Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death.
Cancer research 2004;64(8):2833-9.
2004: Mireille Van Gele; Glen M Boyle; Anthony L Cook; Jo Vandesompele; Tom Boonefaes; Pieter Rottiers; Nadine Van Roy; Anne De Paepe; Peter G Parsons; J Helen Leonard; Frank Speleman
Gene-expression profiling reveals distinct expression patterns for Classic versus Variant Merkel cell phenotypes and new classifier genes to distinguish Merkel cell from small-cell lung carcinoma.
Oncogene 2004;23(15):2732-42.
2004: David Chin; Glen M Boyle; Peter G Parsons; William B Coman
What is transforming growth factor-beta (TGF-beta)?
British journal of plastic surgery 2004;57(3):215-21.
2003: J Helen Leonard; Lisa H Marks; Wei Chen; Anthony L Cook; Glen M Boyle; Darren J Smit; Darren L Brown; Jennifer L Stow; Peter G Parsons; Richard A Sturm
Screening of human primary melanocytes of defined melanocortin-1 receptor genotype: pigmentation marker, ultrastructural and UV-survival studies.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 2003;16(3):198-207.
2003: Effie Ablett; David C Whiteman; Glen M Boyle; Adèle C Green; Peter G Parsons
Induction of metallothionein in human skin by routine exposure to sunlight: evidence for a systemic response and enhanced induction at certain body sites.
The Journal of investigative dermatology 2003;120(2):318-24.
2003: D Visala Rao; Glen M Boyle; Peter G Parsons; Kenneth Watson; Graham L Jones
Influence of ageing, heat shock treatment and in vivo total antioxidant status on gene-expression profile and protein synthesis in human peripheral lymphocytes.
Mechanisms of ageing and development 2003;124(1):55-69.
2003: David C Whiteman; Robyn M Brown; Chunxia Xu; Christine L Paterson; David Miller; Peter G Parsons
A rapid method for determining recent sunscreen use in field studies.
Journal of photochemistry and photobiology. B, Biology 2003;69(1):59-63.
2002: Tom Sculley; Marion Buck; Brian Gabrielli; Peter G Parsons; Kenia G Krauer
A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease.
Transplantation 2002;73(2):271-9.
2001: Andrew Burgess; Sandra Pavey; Robyn Warrener; Lisa-Jane K Hunter; TJ Piva; Elizabeth A Musgrove; Nicholas Saunders; Peter G Parsons; Brian Gabrielli
Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity.
Molecular pharmacology 2001;60(4):828-37.
2001: H Brinkmann; Alison L Dahler; Claudia Popa; Magdalena M Serewko; Peter G Parsons; Brian Gabrielli; Andrew Burgess; Nicholas A Saunders
Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts.
The Journal of biological chemistry 2001;276(25):22491-9.
2001: C Xu; A Green; A Parisi; Peter G Parsons
Photosensitization of the sunscreen octyl p-dimethylaminobenzoate by UVA in human melanocytes but not in keratinocytes.
Photochemistry and photobiology 2001;73(6):600-4.
2001: Neil Box; David L Duffy; R E Irving; Anne Russell; Wei Chen; L R Griffyths; Peter G Parsons; Adèle C Green; Richard A Sturm
Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma.
The Journal of investigative dermatology 2001;116(2):224-9.
2000: Darren J Smit; Aaron G Smith; Peter G Parsons; George E O Muscat; Richard A Sturm
Domains of Brn-2 that mediate homodimerization and interaction with general and melanocytic transcription factors.
European journal of biochemistry / FEBS 2000;267(21):6413-22.
2000: L Qiu; Andrew Burgess; David P Fairlie; H Leonard; Peter G Parsons; Brian Gabrielli
Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.
Molecular biology of the cell 2000;11(6):2069-83.
2000: K T Andrews; A Walduck; Michael J Kelso; David P Fairlie; Allan Saul; Peter G Parsons
Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents.
International journal for parasitology 2000;30(6):761-8.
2000: L Qiu; M Zhang; Richard A Sturm; brooke gardiner; Ian D Tonks; G Kay; Peter G Parsons
Inhibition of melanin synthesis by cystamine in human melanoma cells.
The Journal of investigative dermatology 2000;114(1):21-7.
1999: D C Whiteman; Peter G Parsons; A C Green
Determinants of melanocyte density in adult human skin.
Archives of dermatological research 1999;291(9):511-6.
1999: Dianne Watters; Peter G Parsons
Critical targets of protein kinase C in differentiation of tumour cells.
Biochemical pharmacology 1999;58(3):383-8.
1999: L Qiu; Michael J Kelso; C Hansen; ML West; David P Fairlie; Peter G Parsons
Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate.
British journal of cancer 1999;80(8):1252-8.
1999: C Xu; Peter G Parsons
Cell cycle delay, mitochondrial stress and uptake of hydrophobic cations induced by sunscreens in cultured human cells.
Photochemistry and photobiology 1999;69(5):611-6.
1999: Glen M Boyle; A J Bodero; Julie Pedley; J Helen Leonard; Peter G Parsons
Transcriptional responses of human melanocytes to solar UV.
Redox report : communications in free radical research 1999;4(6):307-8.
1998: Julie Pedley; A Pettit; Peter G Parsons
Inhibition of Ku autoantigen binding activity to the E2F motif after ultraviolet B irradiation of melanocytic cells.
Melanoma research 1998;8(6):471-81.
1998: Effie Ablett; Julie Pedley; P A Dannoy; Richard A Sturm; Peter G Parsons
UVB-specific regulation of gene expression in human melanocytic cells: cell cycle effects and implication in the generation of melanoma.
Mutation research 1998;422(1):31-41.
1998: D C Whiteman; Peter G Parsons; A C Green
p53 expression and risk factors for cutaneous melanoma: a case-control study.
International journal of cancer. Journal international du cancer 1998;77(6):843-8.
1998: M T Hayes; J Bartley; Peter G Parsons
In vitro evaluation of fotemustine as a potential agent for limb perfusion in melanoma.
Melanoma research 1998;8(1):67-75.
1998: Aaron G Smith; G Brightwell; S E Smit; Peter G Parsons; Richard A Sturm
Redox regulation of Brn-2/N-Oct-3 POU domain DNA binding activity and proteolytic formation of N-Oct-5 during melanoma cell nuclear extraction.
Melanoma research 1998;8(1):2-10.
1997: Ying Dong; Michael D Walsh; Margaret C Cummings; RG Wright; Soo-Keat Khoo; Peter G Parsons; Michael A McGuckin
Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours.
The Journal of pathology 1997;183(3):311-7.
1997: M Castellano; Pam Pollock; Marilyn K Walters; L E Sparrow; L M Down; Brian Gabrielli; Peter G Parsons; Nicholas K Hayward
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer research 1997;57(21):4868-75.
1997: M T Hayes; J Bartley; Peter G Parsons; Geoff Eaglesham; arungundrum prakash
Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity.
Biochemistry 1997;36(35):10646-54.
1997: Ying Dong; Michael D Walsh; Michael A McGuckin; Margaret C Cummings; Brian Gabrielli; G R Wright; TG Hurst; Soo-Keat Khoo; Peter G Parsons
Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer.
International journal of cancer. Journal international du cancer 1997;74(4):407-15.
1997: Peter G Parsons; C Hansen; David P Fairlie; ML West; P A Danoy; Richard A Sturm; I S Dunn; Julie Pedley; Effie Ablett
Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells.
Biochemical pharmacology 1997;53(11):1719-24.
1997: Ying Dong; S J Berners-Price; D R Thorburn; Toni M Antalis; J Dickinson; TG Hurst; L Qiu; Soo-Keat Khoo; Peter G Parsons
Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumor cell lines: targets for therapy.
Biochemical pharmacology 1997;53(11):1673-82.
1997: Kay A O Ellem; Michael G E O'Rourke; G R Johnson; G Parry; Ihor Misko; Christopher W Schmidt; Peter G Parsons; Scott R Burrows; S Cross; AH Fell; C L Li; J R Bell; P J Dubois; Denis Moss; Michael F Good; A Kelso; LK Cohen; Glenn Dranoff; Richard C Mulligan
A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy.
Cancer immunology, immunotherapy : CII 1997;44(1):10-20.
1997: C Hansen; Effie Ablett; A Green; Richard A Sturm; I S Dunn; David P Fairlie; ML West; Peter G Parsons
Biphasic response of the metallothionein promoter to ultraviolet radiation in human melanoma cells.
Photochemistry and photobiology 1997;65(3):550-5.
1997: Ying Dong; Michael D Walsh; Michael A McGuckin; Brian Gabrielli; Margaret C Cummings; RG Wright; TG Hurst; Soo-Keat Khoo; Peter G Parsons
Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis.
International journal of cancer. Journal international du cancer 1997;74(1):57-63.
1997: Z Wu; Michael S Roberts; Peter G Parsons; janine thomas
Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model.
Melanoma research 1997;7(1):19-26.
1997: ZY Wu; janine thomas; Peter G Parsons; Michael S Roberts
The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.
British journal of cancer 1997;75(8):1160-6.
1996: Julie Pedley; Effie Ablett; A Pettit; J Meyer; I S Dunn; Richard A Sturm; Peter G Parsons
Inhibition of retinoblastoma protein translation by UVB in human melanocytic cells and reduced cell cycle arrest following repeated irradiation.
Oncogene 1996;13(6):1335-42.
1995: Richard A Sturm; B J O'Sullivan; Neil Box; A G Smith; S E Smit; E R Puttick; Peter G Parsons; I S Dunn
Chromosomal structure of the human TYRP1 and TYRP2 loci and comparison of the tyrosinase-related protein gene family.
Genomics 1995;29(1):24-34.
1995: J A Thomson; K Murphy; E Baker; G R Sutherland; Peter G Parsons; Richard A Sturm; F Thomson
The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells.
Oncogene 1995;11(4):691-700.
1995: Pam Pollock; F Yu; L Qiu; Peter G Parsons; Nicholas K Hayward
Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines.
Oncogene 1995;11(4):663-8.
1994: J Clark; A J Grabs; Peter G Parsons; janine thomas; R S Addison; Michael S Roberts
Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma.
Melanoma research 1994;4(6):365-70.
1994: G Le Gros; X M Zhang; Peter G Parsons
Alteration of tyrosinase activity in human melanocytes and melanoma cells by histamine H2 and H3 ligands.
Melanoma research 1994;4(6):359-64.
1994: Richard A Sturm; B J O'Sullivan; J A Thomson; N Jamshidi; Julie Pedley; Peter G Parsons
Expression studies of pigmentation and POU-domain genes in human melanoma cells.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 1994;7(4):235-40.
1994: J A Thomson; J H Leonard; K McGregor; Richard A Sturm; Peter G Parsons
A nonconsensus octamer-recognition sequence (TAATGARAT-motif) identifies a novel DNA binding protein in human Merkel cell carcinoma cell lines.
International journal of cancer. Journal international du cancer 1994;58(2):285-90.
1994: Graeme J Walker; J M Palmer; Marilyn K Walters; Derek J Nancarrow; Peter G Parsons; Nicholas K Hayward
Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma.
International journal of cancer. Journal international du cancer 1994;58(2):203-6.
1994: G A Fechner; J Michel; Richard A Sturm; J J Jacobs; Peter G Parsons
Reduction of DNA synthesis, pigment synthesis, pigmentation gene mRNA and resistance to UVB in human melanoma cells treated with analogues of a histamine (H2) agonist.
Biochemical pharmacology 1994;48(1):121-30.
1994: G A Fechner; J J Jacobs; Peter G Parsons
Dimaprit analogues inhibit tyrosinase via a disulphide breakdown product independently of the histamine H2 receptor.
Biochemical and biophysical research communications 1994;201(2):687-93.
1994: Graeme J Walker; J M Palmer; Marilyn K Walters; Derek J Nancarrow; Peter G Parsons; Nicholas K Hayward
Refined localization of the melanoma (MLM) gene on chromosome 9p by analysis of allelic deletions.
Oncogene 1994;9(3):819-24.
1993: Margaret C Cummings; C M Furnival; Peter G Parsons; E Townsend
PCNA immunostaining in breast cancer.
The Australian and New Zealand journal of surgery 1993;63(8):630-6.
1993: G A Fechner; J J Jacobs; Peter G Parsons
Inhibition of melanogenesis in human melanoma cells by novel analogues of the partial histamine (H2) agonist nordimaprit.
Biochemical pharmacology 1993;46(1):47-54.
1993: J A Thomson; Peter G Parsons; Richard A Sturm
In vivo and in vitro expression of octamer binding proteins in human melanoma metastases, brain tissue, and fibroblasts.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 1993;6(1):13-22.
1992: Georgia Chenevix-Trench; J Leary; J Kerr; J Michel; Richard F Kefford; TG Hurst; Peter G Parsons; M Friedlander; Soo-Keat Khoo
Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus.
Oncogene 1992;7(6):1059-65.
1992: G A Fechner; Peter G Parsons; M T McEwan; J J Jacobs; H Takahashi
Antiproliferative and depigmenting effects of the histamine (H2) agonist dimaprit and its derivatives on human melanoma cells.
Biochemical pharmacology 1992;43(10):2083-90.
1992: Ian P Hayward; TG Hurst; Peter G Parsons; Soo-Keat Khoo
Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas.
International journal of cell cloning 1992;10(3):182-9.
1992: H Takahashi; Peter G Parsons
Rapid and reversible inhibition of tyrosinase activity by glucosidase inhibitors in human melanoma cells.
The Journal of investigative dermatology 1992;98(4):481-7.
1992: R W Moni; Peter G Parsons; Ronald J Quinn; R J Willis
Critical micelle concentration and hemolytic activity--a correlation suggested by the marine sterol, halistanol trisulfate.
Biochemical and biophysical research communications 1992;182(1):115-20.
1992: H Takahashi; R Schumann; R Quinn; T A Briscoe; Peter G Parsons
Isomers of a marine diterpene distinguish sublines of human melanoma cells on the basis of apoptosis, cell cycle arrest and differentiation markers.
Melanoma research 1992;1(5-6):359-66.
1992: E Townsend; R Moni; R Quinn; Peter G Parsons
Reversible depigmentation of human melanoma cells by halistanol trisulphate, a novel marine sterol.
Melanoma research 1992;1(5-6):349-57.
1991: M T McEwan; Peter G Parsons
Regulation of tyrosinase expression and activity in human melanoma cells via histamine receptors.
The Journal of investigative dermatology 1991;97(5):868-73.
1991: Richard A Sturm; F Bisshop; H Takahashi; Peter G Parsons
A melanoma octamer binding protein is responsive to differentiating agents.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1991;2(10):519-24.
1991: Peter G Parsons; D Favier; M McEwan; H Takahashi; K Jimbow; S Ito
Action of cysteaminylphenols on human melanoma cells in vivo and in vitro: 4-S-cysteaminylphenol binds protein disulphide isomerase.
Melanoma research 1991;1(2):97-104.
1991: John H Kearsley; J Helen Leonard; H Takahashi; D Battistutta; Peter G Parsons; Denis Moss
Prognostic significance of monoclonal antibody 3H-1 reactivity with squamous-cell head-and-neck cancers.
International journal of cancer. Journal international du cancer 1991;47(6):853-7.
1991: Peter G Parsons; J Helen Leonard; John H Kearsley; H Takahashi; X Lin-Jian; Denis Moss
Characterization of a novel monoclonal antibody, 3H-1, reactive with squamoproliferative lesions and squamous-cell cancers.
International journal of cancer. Journal international du cancer 1991;47(6):847-52.
1991: H Takahashi; G M Strutton; Peter G Parsons
Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody.
Histopathology 1991;18(3):221-7.
1990: Peter G Parsons; J Lean; E P Kable; D Favier; Soo-Keat Khoo; TG Hurst; R S Holmes; A J Bellet
Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines.
Biochemical pharmacology 1990;40(12):2641-9.
1990: Soo-Keat Khoo; TG Hurst; John H Kearsley; G Dickie; K Free; Peter G Parsons; S Whitaker; B Ward
Prognostic significance of tumor ploidy in patients with advanced ovarian carcinoma.
Gynecologic oncology 1990;39(3):284-8.
1990: Peter G Parsons; H Takahashi; J Candy; B Meyers; J Vickers; W R Kelly; I Smith; P Spradbrow
Histopathology of melanocytic lesions in goats and establishment of a melanoma cell line: a potential model for human melanoma.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 1990;3(6):297-305.
1990: H Takahashi; Peter G Parsons
In vitro phenotypic alteration of human melanoma cells induced by differentiating agents: heterogeneous effects on cellular growth and morphology, enzymatic activity, and antigenic expression.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 1990;3(5):223-32.
1990: P Musk; A Stowers; Peter G Parsons
Effects of antimetabolites on adenovirus replication in sensitive and resistant human melanoma cell lines.
Biochemical pharmacology 1990;39(4):631-7.
1990: J Lean; Peter G Parsons; A B Awaluddin; J J Jacobs; D J Maddalena; J G Wilson; Soo-Keat Khoo; C Ward
Genotoxicity and cell cycle effects of platinum-based imaging agents in cisplatin-resistant human tumour cells.
Cancer chemotherapy and pharmacology 1990;26(1):42-6.
1990: H Takahashi; Peter G Parsons; D Favier; M McEwan; G M Strutton; Y Akutsu; K Jimbow
Complementary expression of melanosomal antigens and constant expression of pigment-independent antigen during the evolution of melanocytic tumours.
Virchows Archiv. A, Pathological anatomy and histopathology 1990;416(6):513-9.
1989: G F Hoyne; P F Boreham; Peter G Parsons; C Ward; B Biggs
The effect of drugs on the cell cycle of Giardia intestinalis.
Parasitology 1989;99 Pt 3():333-9.
1989: P Musk; R Campbell; J Staples; D J Moss; Peter G Parsons
Solar and UVC-induced mutation in human cells and inhibition by deoxynucleosides.
Mutation research 1989;227(1):25-30.
1989: K Maynard; Peter G Parsons; T Cerny; G P Margison
Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines.
Cancer research 1989;49(17):4813-7.
1989: Soo-Keat Khoo; TG Hurst; M J Webb; G Dickie; John H Kearsley; Peter G Parsons; E V Mackay
Clinical value of in vitro drug sensitivity testing based on short-term effects on DNA and RNA metabolism in ovarian cancer.
Journal of surgical oncology 1989;41(3):201-5.
1989: E P Kable; D Favier; Peter G Parsons
Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
Cancer research 1989;49(9):2327-31.
1989: Peter G Parsons; J Lean; Soo-Keat Khoo; J Lark
Effects of adriamycin and etoposide on the replication of adenovirus 5 in sensitive and resistant human tumour cells.
Biochemical pharmacology 1989;38(1):31-7.
1989: E P Kable; Peter G Parsons
Melanin synthesis and the action of L-dopa and 3,4-dihydroxybenzylamine in human melanoma cells.
Cancer chemotherapy and pharmacology 1989;23(1):1-7.
1989: M McEwan; Peter G Parsons; D J Moss; S Burrows; D Stenzel; C J Bishop; G M Strutton
Monoclonal antibody against a melanosomal protein in melanotic and amelanotic human melanoma cells.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 1989;2(1):1-7.
1988: Soo-Keat Khoo; TG Hurst; M J Webb; G Dickie; John H Kearsley; Peter G Parsons; E V Mackay
Cisplatin chemotherapy of ovarian cancer: is short-term in vitro chemosensitivity predictive of long-term patient survival?
The Australian & New Zealand journal of obstetrics & gynaecology 1988;28(4):313-7.
1988: M G Lihou; P J Smith; Peter G Parsons
Sensitivity of human neuroblastoma to activated dacarbazine: relationships between cell survival, methyltransferase activity and activation of adenovirus-5.
European journal of cancer & clinical oncology 1988;24(6):991-8.
1988: E P Kable; Peter G Parsons
Potency, selectivity and cell cycle dependence of catechols in human tumour cells in vitro.
Biochemical pharmacology 1988;37(9):1711-5.
1988: Soo-Keat Khoo; TG Hurst; M J Webb; G Dickie; John H Kearsley; Peter G Parsons; E V Mackay
Measurement of tumor cell activity in short-term primary culture. Clinical significance in women with ovarian cancer.
Cancer 1988;61(8):1579-86.
1988: M McEwan; Peter G Parsons; D J Moss
Monoclonal antibody against human tyrosinase and reactive with melanotic and amelanotic melanoma cells.
The Journal of investigative dermatology 1988;90(4):515-9.